Results 81 to 88 of about 1,008 (88)

68Ga/177Lu-labeled DOTA-TATE shows similar imaging and biodistribution in neuroendocrine tumor model

Tumor Biology, 2017
Nan Li, Xia Chuanqin, Zhi Yang
exaly  

Results of Individual Patient Dosimetry in Peptide Receptor Radionuclide Therapy with 177Lu DOTA-TATE and 177Lu DOTA-NOC

Cancer Biotherapy and Radiopharmaceuticals, 2007
Richard P Baum
exaly  

Prevention and Management of Hormonal Crisis during Theragnosis with LU-DOTA-TATE in Neuroendocrine Tumors. A Systematic Review and Approach Proposal

Journal of Clinical Medicine, 2020
Juan Francisco Merino-Torres, Martín López-de-la-Torre, María Isabel Del Olmo-Garcia   +2 more
exaly  

Toxicity of a combined therapy using the mTOR-inhibitor everolimus and PRRT with [177Lu]Lu-DOTA-TATE in Lewis rats

EJNMMI Research, 2020
Lena Kaiser, Marcus Hacker, Katja Steiger   +2 more
exaly  

Preparation of Patient Doses of 177Lu-DOTA-TATE Using Indigenously Produced 177Lu: The Indian Experience

Cancer Biotherapy and Radiopharmaceuticals, 2011
Tapas Das, Sharmila Banerjee, Sudipta Chakraborty   +2 more
exaly  

Dose escalation of an Evans blue–modified radiolabeled somatostatin analog 177Lu-DOTA-EB-TATE in the treatment of metastatic neuroendocrine tumors

European Journal of Nuclear Medicine and Molecular Imaging, 2019
Xiaoyuan Chen, Qingxing Liu, Zhaohui Zhu
exaly  

Preparation of DOTA-TATE and DOTA-NOC freeze-dried kits for formulation of patient doses of 177Lu-labeled agents and their comparison for peptide receptor radionuclide therapy application

Journal of Radioanalytical and Nuclear Chemistry, 2014
Haladhar Dev Sarma, Ajit Shinto, Tapas Das   +2 more
exaly  

Ga-Autoclabeling of DOTA-TATE and DOTA-NOC

Applied Radiation and Isotopes, 2012
exaly